BNP Paribas Financial Markets Acquires 44,732 Shares of Krystal Biotech, Inc. $KRYS

BNP Paribas Financial Markets grew its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 487.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 53,911 shares of the company’s stock after purchasing an additional 44,732 shares during the quarter. BNP Paribas Financial Markets’ holdings in Krystal Biotech were worth $13,291,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of KRYS. Royal Bank of Canada boosted its stake in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC boosted its stake in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after acquiring an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after acquiring an additional 688 shares during the last quarter. Empowered Funds LLC bought a new position in Krystal Biotech during the 1st quarter worth approximately $218,000. Finally, Cetera Investment Advisers boosted its stake in Krystal Biotech by 107.9% during the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after acquiring an additional 2,255 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 642 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $310.00 price objective on shares of Krystal Biotech in a research note on Monday, June 1st. Wolfe Research assumed coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They issued a “peer perform” rating on the stock. Evercore reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Guggenheim lifted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Jefferies Financial Group lifted their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $301.00 on Monday. Krystal Biotech, Inc. has a 12-month low of $127.99 and a 12-month high of $319.48. The company has a market capitalization of $8.87 billion, a PE ratio of 40.24 and a beta of 0.53. The firm’s 50 day moving average is $282.39 and its 200-day moving average is $264.58.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.